Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORION-13 inclisiran study in adolescents with homozygous familial hypercholesterolemia
2020-002755-38Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Inclisiran then open-label inclisiran with Placebo then open-label inclisiran (2 arms). Primary endpoint: Percentage change in LDL-C from baseline to Day 330. Started Dec 2020; status: completed.
02
Drugs
inclisiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on 2020-002755-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002755-38.